Liver Disease Treatment Market- by Disease Type, by Treatment Type, by End-users, By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030

Report Code: HCR 0334 Report Format: PDF + Excel

Liver Disease Treatment Market Overview

The Liver Disease Treatment Market Size is forecast to reach $ 35970.26 Million by 2030, at a CAGR of 6.45% during forecast period 2024-2030. Cirrhosis can result from liver diseases. When additional scar tissue replaces healthy liver tissue, the liver can no longer function correctly. Untreated liver disease can lead to liver cancer and liver failure. Life-threatening liver diseases include acute liver failure, severe cirrhosis, liver cancer and hepatitis. According to the Centers for Disease Control and Prevention, each year in the United States, about 25,000 men and 11,000 women get liver cancer and about 19,000 men and 9,000 women die from the disease. However, patients with certain illnesses may be able to have a liver transplant to help preserve their lives. During a liver transplant operation, the damaged liver of the patient is replaced with a healthy liver from a donor. Despite the possibility of long donor waiting lists or difficulties finding compatible organs, there are other life-saving treatments available for patients. The diagnosis would affect how patients are treated for liver diseases. In most cases, as part of a medical program that includes regular monitoring of liver function, some liver diseases can be managed with lifestyle changes, such as quitting drinking or decreasing weight. Other liver diseases may need surgery or medical intervention to be resolved. A liver transplant may ultimately be necessary for the treatment of liver diseases that result in or have already caused liver failure.

Liver Disease Treatment Market Report Coverage

The report: “Liver Disease Treatment Market – Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Liver Disease Treatment Market.

By Disease Type: Genetic Disorders, Cancer, Hepatitis, Non-Alcoholic Fatty Liver Disease (NAFLD), Autoimmune Diseases and Others.
By Treatment Type: Vaccines, Immunoglobulins, Targeted Therapy, Antiviral Drugs, Chemotherapy, Corticosteroids, Immunosuppressants and Others.
By End-users: Hospitals, Specialty Clinics, Diagnostic Laboratories and Others.
By Geography: North America (the U.S., Canada and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia and New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

  • North America held the largest market share in 2022. This is due to a rise in R&D investments by healthcare facilities and research organizations for the discovery of novel medications in the region. Asia-Pacific is projected to grow fastest during the forecast period of 2023-2028, as liver disease incidence is increasing in the region and the healthcare system is gradually improving.
  • The market for liver disease treatment is anticipated to be driven by an increase in liver cirrhosis cases as a result of an increase in hepatitis infections.
  • A rapidly changing lifestyle that includes increased alcohol intake and an unbalanced diet is to blame for the growth in the number of people with liver diseases. Therefore, an increase in disease prevalence is anticipated to drive the expansion of the global market.
  • A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Liver Disease Treatment Market Report.

Liver Disease Treatment: Market Share (%) by region, 2022

Liver Disease Treatment Market

For More Details on This Report - Request for Sample

Liver Disease Treatment Market Segment Analysis – by Disease Type

Based on disease type, the Liver Disease Treatment market is further segmented into genetic disorders, cancer, hepatitis, non-alcoholic fatty liver disease (NAFLD), autoimmunity diseases and others. The Hepatitis segment held the largest revenue market share in 2022, as hepatitis is a common viral infection that results in liver inflammation. Among the various types of cirrhosis, hepatitis B and C are the most common. Though they occur less frequently, hepatitis A and D are also known to cause significant liver scarring. The Pan American Health Organization 2022 estimated that there are 23,000 fatalities and 10,000 new cases of hepatitis B per year.

However, the Non-Alcoholic Fatty Liver Disease (NAFLD) segment is estimated to grow at the fastest CAGR of 11.6% over the forecast period of 2023–2028, owing to an increase in the prevalence of obesity globally and an increase in the incidence of diabetes. A number of diseases brought on by an accumulation of fat in the liver are together referred to as non-alcoholic fatty liver disease (NAFLD). Obese or overweight individuals frequently exhibit it. Although there is a strong correlation between NAFLD and obesity, 5–10% of people who are thin have the condition, according to the National Library of Medicine (NLM).

Liver Disease Treatment Market Segment Analysis – by Treatment Type

Based on treatment type, the Liver Disease Treatment market is further segmented into vaccines, immunoglobulins, targeted therapy, antiviral drugs, chemotherapy, corticosteroids, immunosuppressants and others. The Antiviral Drugs segment held the largest revenue market share in 2022, owing to its significant advantages and rising investments in the field. According to the Centers for Disease Control and Prevention (CDC), 1 out of every 3 patients with health insurance receives treatment with direct-acting antivirals (DAAs) a year following a hepatitis C diagnosis. However, the Vaccine segment is anticipated to grow at the fastest CAGR of 12.5% over the forecast period of 2023–2028, as medical disorders like liver disease make vaccinations extremely important and liver disease can now be better prevented. Hepatitis A and B vaccinations, for instance, have lowered the prevalence of acute viral hepatitis.

Liver Disease Treatment Market Segment Analysis – by Geography

Based on geography, the North American Liver Disease Treatment Market accounted for a 32% revenue share in 2022. Rising alcohol and drug addictions are the main causes of the rise in liver disease diagnoses. The market for treating liver diseases in the region would be driven by the rise in the population with liver diseases. According to an article by Single Care, alcohol consumption disorders affect more than 14 million American adults and binge drinking is responsible for 95,000 fatalities annually. However, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period of 2023–2028, owing to rising investments in the development of healthcare services and the rising prevalence of liver diseases in the region.

Liver Disease Treatment Market Drivers

A Rise in the Prevalence of Liver Diseases:

Liver diseases continue to be very common throughout the world. According to Liver Foundation, the number of Americans who suffer from liver disease exceeds 100 million. Liver disease has been identified in 4.5 million people (1.8%) in the U.S. in 2022. The number of people with liver diseases has increased as a result of unhealthy lifestyles, a lack of exercise and extremely unhealthy diets. Hepatitis, non-alcoholic fatty liver and other autoimmune illnesses are becoming more and more common among the aging geriatric population. Significantly increasing alcohol consumption is also to blame for the increase in patients. The global market for liver disease treatment would be driven by the increasing number of patients receiving various treatments for liver diseases.

Increasing R&D Investments:

Healthcare organizations have spent money on research and development of better medications, equipment and treatment choices in response to the rising demand for Liver Disease Treatments. The development of new liver disease medications has received significant funding from biotech companies and research institutions worldwide. According to the National Library of Medicine (NLM), in 2020, the drug clinical trial registration and information disclosure platform made the results of 751 clinical trials involving liver diseases available. Of these, 574 (76.4%) used chemical drugs, 128 (17.0%) used biological products and 49 (6.5%) used natural drugs from traditional Chinese medicine. Additionally, 732 of these trials are ongoing or finished, while 19 are suspended. The latter comprises 124 biological product trials, 48 natural medicine trials and 560 chemical drug trials. The market for treating liver diseases would become more competitive and effective as a result of advances and breakthroughs. This is anticipated to give rise to profitable prospects for market participants and boost the market's expansion.

Liver Disease Treatment Market Challenge

High-cost Medications and Treatments to Cure Liver Diseases:

The medicines and treatments that are used to treat liver diseases and related ailments require a significant number of financial resources. According to the article "Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults," the total cost of alcoholic cirrhosis hospitalizations was $22.7 billion in 2020 and the increased cost of the hepatitis C virus was $22.6 billion across all etiologies. The presence of cirrhosis, complications of cirrhosis and comorbidities added to the chronic lung disease burden. The efficacy and safety of these treatments are improved by market players using cutting-edge technologies and innovations. But these technologies are costly and drug development is an expensive endeavor. The costs are also increased by the difficult regulatory clearances and multiple medication testing trials. Thus, the market's expansion would be hampered by the high price of therapies for liver diseases.

Key Market Players:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Liver Disease Treatment Market. The top 10 companies in the Liver Disease Treatment Market are:

1. Pfizer Inc.
2. Abbott Laboratories
3. Novartis AG
4. Eli Lilly and Company
5. Gilead Sciences
6. Alnylam Pharmaceuticals Inc.
7. AbbVie Inc.
8. Zydus Pharmaceuticals Inc.
9. Enanta Pharmaceuticals Inc.
10. Mirum Pharmaceuticals

Recent Developments

  • In June 2021, the American biopharmaceutical company Gilead Sciences introduced Hepcludex, an antiviral drug that cures the hepatitis D virus (HDV). Hepcludex is a top-notch entry inhibitor that has been approved by the European Commission and registered in Russia as Myrcludex B.
  • In January 2021, Novartis Institutes for BioMedical Research and Alnylam partnered to use Alnylam's siRNA technology to suppress a target. This work could result in the creation of a therapy that encourages the formation of functioning liver cells and offers patients with liver failure an option for transplantation.
  • In April 2020, Alnylam Pharmaceuticals Inc. and Dicerna Pharmaceuticals Inc. partnered to develop and promote investigational RNAi therapies for the treatment of liver diseases caused by alpha-1 antitrypsin deficiency.

For more Lifesciences and Healthcare Market reports, please click here

1. Liver Disease Treatment - Overview
    1.1. Definitions and Scope
2. Liver Disease Treatment - Executive Summary
3. Liver Disease Treatment – Market Landscape
    3.1. Company Benchmarking - Key Companies
    3.2. Financial Analysis – Key Companies
    3.3. Market Share Analysis – Key Companies
    3.4. Patent Analysis - Global
    3.5. Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Liver Disease Treatment – Startup Company Scenario 
    4.1. Investment
    4.2. Revenue
    4.3. Venture Capital and Funding Scenario
5. Liver Disease Treatment – Market Entry Scenario Premium 
    5.1. Regulatory Scenario
    5.2. New Business and Ease of Doing business index
    5.3. Case Studies of Successful Ventures
6. Liver Disease Treatment - Forces
    6.1. Market Drivers
    6.2. Market Constraints
    6.3. Porter's five force model
        6.3.1. Bargaining power of suppliers
        6.3.2. Bargaining powers of customers
        6.3.3. Threat of new entrants
        6.3.4. Rivalry among existing players
        6.3.5. Threat of substitutes
7. Liver Disease Treatment – Strategic Analysis
    7.1. Value Chain Analysis
    7.2. Opportunities Analysis
    7.3. Market Life Cycle Analysis
8. Liver Disease Treatment – by Disease Type
    8.1. Genetic Disorders
    8.2. Cancer
    8.3. Hepatitis
    8.4. Non-alcoholic Fatty Liver Disease (NAFLD)
    8.5. Autoimmune Diseases
    8.6. Others
9. Liver Disease Treatment – by Treatment Type
    9.1. Vaccines
    9.2. Immunoglobulins
    9.3. Targeted Therapy
    9.4. Antiviral Drugs
    9.5. Chemotherapy
    9.6. Corticosteroids
    9.7. Immunosuppressants
    9.8. Others
10. Liver Disease Treatment – by End-user
    10.1. Hospitals
    10.2. Clinics
    10.3. Diagnostic Laboratories
    10.4. Others
11. Liver Disease Treatment - by Geography
    11.1. North America
        11.1.1. The US
        11.1.2. Canada
        11.1.3. Mexico
    11.2. South America
        11.2.1. Brazil
        11.2.2. Argentina
        11.2.3. Colombia
        11.2.4. Chile
        11.2.5. The Rest of South America
    11.3. Europe
        11.3.1. The UK
        11.3.2. Germany
        11.3.3. France
        11.3.4. Italy
        11.3.5. Spain
        11.3.6. Russia
        11.3.7. The Rest of Europe
    11.4. Asia-Pacific
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. South Korea
        11.4.5. Australia and New Zealand
        11.4.6. The Rest of APAC
    11.5. The Rest of the World
        11.5.1. The Middle East
        11.5.2. Africa
12. Liver Disease Treatment - Market Entropy
    12.1. New service launches
    12.2. M&As, collaborations, JVs and partnerships
13. Liver Disease Treatment – Industry Competition Landscape 
    13.1. Market Share Analysis
        13.1.1. Market Share by Region – Key Companies
        13.1.2. Market Share by Country – Key Companies
    13.2. Competition Matrix
    13.3. Best Practices for Companies
14. Liver Disease Treatment – Key Company List by Country Premium 
15. Liver Disease Treatment Company Analysis
    15.1. Abbott Laboratories
    15.2. Novartis AG
    15.3. Sanofi AG
    15.4. Abbvie Inc
    15.5. F.Hoffman-La Roche AG
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.

List of Tables:

Table 1 Liver Disease Treatment Market Overview 2023-2030
Table 2 Liver Disease Treatment Market Leader Analysis 2023-2030 (US$)
Table 3 Liver Disease Treatment Market Product Analysis 2023-2030 (US$)
Table 4 Liver Disease Treatment Market End User Analysis 2023-2030 (US$)
Table 5 Liver Disease Treatment Market Patent Analysis 2013-2023* (US$)
Table 6 Liver Disease Treatment Market Financial Analysis 2023-2030 (US$)
Table 7 Liver Disease Treatment Market Driver Analysis 2023-2030 (US$)
Table 8 Liver Disease Treatment Market Challenges Analysis 2023-2030 (US$)
Table 9 Liver Disease Treatment Market Constraint Analysis 2023-2030 (US$)
Table 10 Liver Disease Treatment Market Supplier Bargaining Power Analysis 2023-2030 (US$)
Table 11 Liver Disease Treatment Market Buyer Bargaining Power Analysis 2023-2030 (US$)
Table 12 Liver Disease Treatment Market Threat of Substitutes Analysis 2023-2030 (US$)
Table 13 Liver Disease Treatment Market Threat of New Entrants Analysis 2023-2030 (US$)
Table 14 Liver Disease Treatment Market Degree of Competition Analysis 2023-2030 (US$)
Table 15 Liver Disease Treatment Market Value Chain Analysis 2023-2030 (US$)
Table 16 Liver Disease Treatment Market Pricing Analysis 2023-2030 (US$)
Table 17 Liver Disease Treatment Market Opportunities Analysis 2023-2030 (US$)
Table 18 Liver Disease Treatment Market Product Life Cycle Analysis 2023-2030 (US$)
Table 19 Liver Disease Treatment Market Supplier Analysis 2023-2030 (US$)
Table 20 Liver Disease Treatment Market Distributor Analysis 2023-2030 (US$)
Table 21 Liver Disease Treatment Market Trend Analysis 2023-2030 (US$)
Table 22 Liver Disease Treatment Market Size 2023 (US$)
Table 23 Liver Disease Treatment Market Forecast Analysis 2023-2030 (US$)
Table 24 Liver Disease Treatment Market Sales Forecast Analysis 2023-2030 (Units)
Table 25 Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 26 Liver Disease Treatment Market By Drug Type, Revenue & Volume, By Vaccines, Antiviral, 2023-2030 ($)
Table 27 Liver Disease Treatment Market By Drug Type, Revenue & Volume, By Corticosteroids, 2023-2030 ($)
Table 28 Liver Disease Treatment Market By Drug Type, Revenue & Volume, By Anabolic Steroids, 2023-2030 ($)
Table 29 Liver Disease Treatment Market By Drug Type, Revenue & Volume, By Antimetabolites, 2023-2030 ($)
Table 30 Liver Disease Treatment Market By Drug Type, Revenue & Volume, By Anti-Rejection Drugs, 2023-2030 ($)
Table 31 Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 32 Liver Disease Treatment Market By Disease, Revenue & Volume, By Hepatitis, 2023-2030 ($)
Table 33 Liver Disease Treatment Market By Disease, Revenue & Volume, By Autoimmune Diseases, 2023-2030 ($)
Table 34 Liver Disease Treatment Market By Disease, Revenue & Volume, By Liver Tumor, 2023-2030 ($)
Table 35 Liver Disease Treatment Market By Disease, Revenue & Volume, By Alcohol Induced Liver Disease, 2023-2030 ($)
Table 36 Liver Disease Treatment Market By Disease, Revenue & Volume, By Chronic Liver Disease, 2023-2030 ($)
Table 49 Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 50 Liver Disease Treatment Market By End Use, Revenue & Volume, By Hospitals, 2023-2030 ($)
Table 51 Liver Disease Treatment Market By End Use, Revenue & Volume, By Adult Liver Disease Treatment Centers, 2023-2030 ($)
Table 52 Liver Disease Treatment Market By End Use, Revenue & Volume, By Ambulatory Surgical Centers, 2023-2030 ($)
Table 55 North America Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 56 North America Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 59 North America Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 60 South america Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 61 South america Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 64 South america Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 65 Europe Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 66 Europe Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 69 Europe Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 70 APAC Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 71 APAC Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 74 APAC Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 75 Middle East & Africa Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 76 Middle East & Africa Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 79 Middle East & Africa Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 80 Russia Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 81 Russia Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 84 Russia Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 85 Israel Liver Disease Treatment Market, Revenue & Volume, By Drug Type, 2023-2030 ($)
Table 86 Israel Liver Disease Treatment Market, Revenue & Volume, By Disease, 2023-2030 ($)
Table 89 Israel Liver Disease Treatment Market, Revenue & Volume, By End Use, 2023-2030 ($)
Table 90 Top Companies 2023 (US$)Liver Disease Treatment Market, Revenue & Volume
Table 91 Product Launch 2023-2030Liver Disease Treatment Market, Revenue & Volume
Table 92 Mergers & Acquistions 2023-2030Liver Disease Treatment Market, Revenue & Volume


List of Figures:

Figure 1 Overview of Liver Disease Treatment Market 2023-2030
Figure 2 Market Share Analysis for Liver Disease Treatment Market 2023 (US$)
Figure 3 Product Comparison in Liver Disease Treatment Market 2023-2030 (US$)
Figure 4 End User Profile for Liver Disease Treatment Market 2023-2030 (US$)
Figure 5 Patent Application and Grant in Liver Disease Treatment Market 2013-2023* (US$)
Figure 6 Top 5 Companies Financial Analysis in Liver Disease Treatment Market 2023-2030 (US$)
Figure 7 Market Entry Strategy in Liver Disease Treatment Market 2023-2030
Figure 8 Ecosystem Analysis in Liver Disease Treatment Market 2023
Figure 9 Average Selling Price in Liver Disease Treatment Market 2023-2030
Figure 10 Top Opportunites in Liver Disease Treatment Market 2023-2030
Figure 11 Market Life Cycle Analysis in Liver Disease Treatment Market
Figure 12 GlobalBy Drug TypeLiver Disease Treatment Market Revenue, 2023-2030 ($)
Figure 13 GlobalBy DiseaseLiver Disease Treatment Market Revenue, 2023-2030 ($)
Figure 16 GlobalBy End UseLiver Disease Treatment Market Revenue, 2023-2030 ($)
Figure 17 Global Liver Disease Treatment Market - By Geography
Figure 18 Global Liver Disease Treatment Market Value & Volume, By Geography, 2023-2030 ($) 
Figure 19 Global Liver Disease Treatment Market CAGR, By Geography, 2023-2030 (%)
Figure 20 North America Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 21 US Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 22 US GDP and Population, 2023-2030 ($)
Figure 23 US GDP – Composition of 2023, By Sector of Origin
Figure 24 US Export and Import Value & Volume, 2023-2030 ($)
Figure 25 Canada Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 26 Canada GDP and Population, 2023-2030 ($)
Figure 27 Canada GDP – Composition of 2023, By Sector of Origin
Figure 28 Canada Export and Import Value & Volume, 2023-2030 ($)
Figure 29 Mexico Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 30 Mexico GDP and Population, 2023-2030 ($)
Figure 31 Mexico GDP – Composition of 2023, By Sector of Origin
Figure 32 Mexico Export and Import Value & Volume, 2023-2030 ($)
Figure 33 South America Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 34 Brazil Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 35 Brazil GDP and Population, 2023-2030 ($)
Figure 36 Brazil GDP – Composition of 2023, By Sector of Origin
Figure 37 Brazil Export and Import Value & Volume, 2023-2030 ($)
Figure 38 Venezuela Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 39 Venezuela GDP and Population, 2023-2030 ($)
Figure 40 Venezuela GDP – Composition of 2023, By Sector of Origin
Figure 41 Venezuela Export and Import Value & Volume, 2023-2030 ($)
Figure 42 Argentina Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 43 Argentina GDP and Population, 2023-2030 ($)
Figure 44 Argentina GDP – Composition of 2023, By Sector of Origin
Figure 45 Argentina Export and Import Value & Volume, 2023-2030 ($)
Figure 46 Ecuador Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 47 Ecuador GDP and Population, 2023-2030 ($)
Figure 48 Ecuador GDP – Composition of 2023, By Sector of Origin
Figure 49 Ecuador Export and Import Value & Volume, 2023-2030 ($)
Figure 50 Peru Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 51 Peru GDP and Population, 2023-2030 ($)
Figure 52 Peru GDP – Composition of 2023, By Sector of Origin
Figure 53 Peru Export and Import Value & Volume, 2023-2030 ($)
Figure 54 Colombia Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 55 Colombia GDP and Population, 2023-2030 ($)
Figure 56 Colombia GDP – Composition of 2023, By Sector of Origin
Figure 57 Colombia Export and Import Value & Volume, 2023-2030 ($)
Figure 58 Costa Rica Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 59 Costa Rica GDP and Population, 2023-2030 ($)
Figure 60 Costa Rica GDP – Composition of 2023, By Sector of Origin
Figure 61 Costa Rica Export and Import Value & Volume, 2023-2030 ($)
Figure 62 Europe Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 63 U.K Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 64 U.K GDP and Population, 2023-2030 ($)
Figure 65 U.K GDP – Composition of 2023, By Sector of Origin
Figure 66 U.K Export and Import Value & Volume, 2023-2030 ($)
Figure 67 Germany Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 68 Germany GDP and Population, 2023-2030 ($)
Figure 69 Germany GDP – Composition of 2023, By Sector of Origin
Figure 70 Germany Export and Import Value & Volume, 2023-2030 ($)
Figure 71 Italy Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 72 Italy GDP and Population, 2023-2030 ($)
Figure 73 Italy GDP – Composition of 2023, By Sector of Origin
Figure 74 Italy Export and Import Value & Volume, 2023-2030 ($)
Figure 75 France Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 76 France GDP and Population, 2023-2030 ($)
Figure 77 France GDP – Composition of 2023, By Sector of Origin
Figure 78 France Export and Import Value & Volume, 2023-2030 ($)
Figure 79 Netherlands Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 80 Netherlands GDP and Population, 2023-2030 ($)
Figure 81 Netherlands GDP – Composition of 2023, By Sector of Origin
Figure 82 Netherlands Export and Import Value & Volume, 2023-2030 ($)
Figure 83 Belgium Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 84 Belgium GDP and Population, 2023-2030 ($)
Figure 85 Belgium GDP – Composition of 2023, By Sector of Origin
Figure 86 Belgium Export and Import Value & Volume, 2023-2030 ($)
Figure 87 Spain Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 88 Spain GDP and Population, 2023-2030 ($)
Figure 89 Spain GDP – Composition of 2023, By Sector of Origin
Figure 90 Spain Export and Import Value & Volume, 2023-2030 ($)
Figure 91 Denmark Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 92 Denmark GDP and Population, 2023-2030 ($)
Figure 93 Denmark GDP – Composition of 2023, By Sector of Origin
Figure 94 Denmark Export and Import Value & Volume, 2023-2030 ($)
Figure 95 APAC Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 96 China Liver Disease Treatment Market Value & Volume, 2023-2030
Figure 97 China GDP and Population, 2023-2030 ($)
Figure 98 China GDP – Composition of 2023, By Sector of Origin
Figure 99 China Export and Import Value & Volume, 2023-2030 ($)Liver Disease Treatment Market China Export and Import Value & Volume, 2023-2030 ($)
Figure 100 Australia Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 101 Australia GDP and Population, 2023-2030 ($)
Figure 102 Australia GDP – Composition of 2023, By Sector of Origin
Figure 103 Australia Export and Import Value & Volume, 2023-2030 ($)
Figure 104 South Korea Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 105 South Korea GDP and Population, 2023-2030 ($)
Figure 106 South Korea GDP – Composition of 2023, By Sector of Origin
Figure 107 South Korea Export and Import Value & Volume, 2023-2030 ($)
Figure 108 India Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 109 India GDP and Population, 2023-2030 ($)
Figure 110 India GDP – Composition of 2023, By Sector of Origin
Figure 111 India Export and Import Value & Volume, 2023-2030 ($)
Figure 112 Taiwan Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 113 Taiwan GDP and Population, 2023-2030 ($)
Figure 114 Taiwan GDP – Composition of 2023, By Sector of Origin
Figure 115 Taiwan Export and Import Value & Volume, 2023-2030 ($)
Figure 116 Malaysia Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 117 Malaysia GDP and Population, 2023-2030 ($)
Figure 118 Malaysia GDP – Composition of 2023, By Sector of Origin
Figure 119 Malaysia Export and Import Value & Volume, 2023-2030 ($)
Figure 120 Hong Kong Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 121 Hong Kong GDP and Population, 2023-2030 ($)
Figure 122 Hong Kong GDP – Composition of 2023, By Sector of Origin
Figure 123 Hong Kong Export and Import Value & Volume, 2023-2030 ($)
Figure 124 Middle East & Africa Liver Disease Treatment Market Middle East & Africa 3D Printing Market Value & Volume, 2023-2030 ($)
Figure 125 Russia Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 126 Russia GDP and Population, 2023-2030 ($)
Figure 127 Russia GDP – Composition of 2023, By Sector of Origin
Figure 128 Russia Export and Import Value & Volume, 2023-2030 ($)
Figure 129 Israel Liver Disease Treatment Market Value & Volume, 2023-2030 ($)
Figure 130 Israel GDP and Population, 2023-2030 ($)
Figure 131 Israel GDP – Composition of 2023, By Sector of Origin
Figure 132 Israel Export and Import Value & Volume, 2023-2030 ($)
Figure 133 Entropy Share, By Strategies, 2023-2030* (%)Liver Disease Treatment Market
Figure 134 Developments, 2023-2030*Liver Disease Treatment Market
Figure 135 Company 1 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 136 Company 1 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 137 Company 1 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 138 Company 2 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 139 Company 2 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 140 Company 2 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 141 Company 3 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 142 Company 3 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 143 Company 3 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 144 Company 4 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 145 Company 4 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 146 Company 4 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 147 Company 5 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 148 Company 5 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 149 Company 5 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 150 Company 6 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 151 Company 6 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 152 Company 6 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 153 Company 7 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 154 Company 7 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 155 Company 7 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 156 Company 8 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 157 Company 8 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 158 Company 8 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 159 Company 9 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 160 Company 9 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 161 Company 9 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 162 Company 10 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 163 Company 10 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 164 Company 10 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 165 Company 11 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 166 Company 11 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 167 Company 11 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 168 Company 12 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 169 Company 12 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 170 Company 12 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 171 Company 13 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 172 Company 13 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 173 Company 13 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 174 Company 14 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 175 Company 14 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 176 Company 14 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)
Figure 177 Company 15 Liver Disease Treatment Market Net Revenue, By Years, 2023-2030* ($)
Figure 178 Company 15 Liver Disease Treatment Market Net Revenue Share, By Business segments, 2023 (%)
Figure 179 Company 15 Liver Disease Treatment Market Net Sales Share, By Geography, 2023 (%)